TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23181643

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Urgency symptoms
Number of subjects: 187
Study: 18978606

Group type: EXPERIMENTAL
Intervention: Video-based perceptual training (N = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (N = 8)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Video-based perceptual training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 16142502

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 or 40 mcg/day)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo or antiresorptive drugs (including hormone replacement therapy and alendronate)
Number of subjects: 5
Study: 14727367

Group type: EXPERIMENTAL
Intervention: Oral antiphlogistic medicinal granules only (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral antiphlogistic medicinal granules + retention enema (Group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Oral antiphlogistic medicinal granules + rectal (Group C)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Antiphlogistic medicinal granules + rectally + hip bath (Group D)
Number of subjects: 160
Study: 11527612

Group type: EXPERIMENTAL
Intervention: Eptifibatide (two 180 microg/kg boluses 10 min apart and continuous infusion of 2 microg/kg per min)
Number of subjects: 2064

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2064

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 2064
Study: 9547132

Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg once a day, titrated to a maximum of 200 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sertraline (2 full years treatment)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (during double-blind phase)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Sertraline (during double-blind phase)
Number of subjects: 59
Study: 8420344

Group type: EXPERIMENTAL
Intervention: 20 micrograms ethinyl estradiol and 150 micrograms desogestrel (n = 15)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinyl estradiol and 75 micrograms gestodene (n = 19)
Number of subjects: 34
Study: 2877884

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SASP)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Pentasa
Number of subjects: 9
Study: 31230147

Group type: EXPERIMENTAL
Intervention: Wheat peptides and fucoidan (WPF)
Number of subjects: 106
Study: 30105816

Group type: EXPERIMENTAL
Intervention: Microneedling combined with PRP
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Microneedling combined with TCA 15% peeling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Microneedling alone
Number of subjects: 24
Study: 27194317

Group type: EXPERIMENTAL
Intervention: Nurse-led lymphoma survivorship clinic with three face-to-face appointments and tailored resources, survivorship care plan and treatment summary (SCP TS).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual post-treatment care.
Number of subjects: 0
Study: 24326536

Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR)
Number of subjects: 1075

Group type: EXPERIMENTAL
Intervention: High users of PHR
Number of subjects: 1075

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1075
Study: 24139256

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride with 12.5 μg/mL epinephrine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20% ethyl aminobenzoate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: physiological saline solution
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 20% ethyl aminobenzoate (cotton ball)
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30-gauge needle insertion
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 33-gauge needle insertion
Number of subjects: 20
Study: 21940510

Group type: EXPERIMENTAL
Intervention: Glucose (75 g)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fructose (75 g)
Number of subjects: 16
Study: 18262151

Group type: COMPARATOR
Intervention: Blind biopsy (Novak's curette)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 319
Study: 16618270

Group type: EXPERIMENTAL
Intervention: Olmesartan (10 to 40 mg)
Number of subjects: 24
Study: 12795037

Group type: EXPERIMENTAL
Intervention: Methotrexate treatment for progressive MS
Number of subjects: 52
Study: 10707514

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Isoflurane anesthesia
Number of subjects: 12
Study: 8793761

Group type: EXPERIMENTAL
Intervention: Pursuit superposition during VOR cancellation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VOR response during CW roll with target light on
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye position change from 20 deg up to 20 deg down during CW roll
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VOR response during rightward rotation while looking 20 deg up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall eye velocities during cancellation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VOR gain reduction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pursuit driven by retinal slip
Number of subjects: 0
Study: 1626732

Group type: EXPERIMENTAL
Intervention: Pentoxifylline, oral administration at a dose of 1,200 mg daily during healing and 400 mg daily during ulcer-free intervals
Number of subjects: 51

Group type: COMPARATOR
Intervention: Deferoxamine, intravenous dose of 20 mg/kg
Number of subjects: 51
Study: 3890639

Group type: EXPERIMENTAL
Intervention: Atropine (0.05 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31780002

Group type: EXPERIMENTAL
Intervention: Foot reflexology (15 min on each foot, total 30 min, twice a week for six weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Routine care for menopause patients
Number of subjects: 90
Study: 28070639

Group type: EXPERIMENTAL
Intervention: Healthy carbohydrate diet (HCD) rich in cereal fibre, arabinoxylan and resistant starch
Number of subjects: 19

Group type: COMPARATOR
Intervention: Refined-carbohydrate western-style diet (WSD)
Number of subjects: 19
Study: 30645840

Group type: EXPERIMENTAL
Intervention: Chinese herbs combined DHEA pretreatment for 8 weeks
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: DHEA pretreatment for 8 weeks
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Chinese herbs combined DHEA pretreatment
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: DHEA pretreatment
Number of subjects: 233
Study: 23877142

Group type: EXPERIMENTAL
Intervention: OxyBand dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Xeroform gauze dressing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: OxyBand dressing and Xeroform gauze dressing
Number of subjects: 20
Study: 22156855

Group type: EXPERIMENTAL
Intervention: Antimicrobial treatment for 8 weeks
Number of subjects: 134
Study: 20501774

Group type: EXPERIMENTAL
Intervention: Behavioral intervention promoting a reduced fat diet
Number of subjects: 230

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 230
Study: 18938291

Group type: EXPERIMENTAL
Intervention: Preparatory intervention before terrorism media exposure
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Terrorism media exposure
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Non-terrorism media broadcast
Number of subjects: 80
Study: 16860046

Group type: EXPERIMENTAL
Intervention: 3-day hormone-free interval (HFI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 4-day hormone-free interval (HFI)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 7-day hormone-free interval (HFI)
Number of subjects: 12
Study: 12826045

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 mg/m2 as a 3-h infusion followed by carboplatin at AUC 6 every 3 weeks for three courses
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel/carboplatin induction regimen
Number of subjects: 52
Study: 11079666

Group type: EXPERIMENTAL
Intervention: Carvedilol treatment
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 8783111

Group type: EXPERIMENTAL
Intervention: Anticoagulation without catheter removal
Number of subjects: 17

Group type: COMPARATOR
Intervention: Anticoagulation with early catheter removal
Number of subjects: 17
Study: 1321056

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (1.6 mg.day‐1 for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg.day‐1 for 3 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose oral dexamethasone (8 mg.day‐1 for 2 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro dexamethasone greater than 10(‐8) M
Number of subjects: 0
Study: 6148382

Group type: EXPERIMENTAL
Intervention: 2 mg LI 32-468
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4 mg LI 32-468
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10 mg LI 32-468
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 120 mg propranolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31682194

Group type: EXPERIMENTAL
Intervention: Mentalization-Based Treatment in a day hospital setting (MBT-DH)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Specialist Treatment as Usual (S-TAU)
Number of subjects: 95
Study: 30448598

Group type: EXPERIMENTAL
Intervention: Besifovir dipivoxil maleate (BSV) 150 mg
Number of subjects: 197

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: BSV (after switching from TDF)
Number of subjects: 197

Group type: COMPARATOR
Intervention: TDF (after switching to BSV)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: BSV
Number of subjects: 197

Group type: COMPARATOR
Intervention: TDF
Number of subjects: 197

Group type: COMPARATOR
Intervention: BSV and TDF
Number of subjects: 197
Study: 28358380

Group type: EXPERIMENTAL
Intervention: Cover sheet added to the permission form (intervention)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard form (control)
Number of subjects: 32
Study: 25287163

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate with magnesium citrate (SPMC) plus bisacodyl
Number of subjects: 365

Group type: COMPARATOR
Intervention: Conventional polyethylene glycol (PEG)
Number of subjects: 365
Study: 23839751

Group type: EXPERIMENTAL
Intervention: Soy protein isolate (20 g daily)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Calcium caseinate (placebo)
Number of subjects: 177
Study: 21863389

Group type: EXPERIMENTAL
Intervention: IV‐PCA (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (n = 30)
Number of subjects: 60
Study: 18645042

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgical treatment
Number of subjects: 83

Group type: COMPARATOR
Intervention: Nonoperative treatment by functional bracing
Number of subjects: 83
Study: 16538011

Group type: COMPARATOR
Intervention: Direct stent alone (Group D)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stent after RESCUE/Thrombuster system (Group R/T)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Stent after thrombus suction using a PercuSurge GuardWire catheter (Group P)
Number of subjects: 77
Study: 12655619

Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (CBT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Group cognitive-behavioral therapy (CBT)
Number of subjects: 60
Study: 11194948

Group type: EXPERIMENTAL
Intervention: 3D-conformal-radiation therapy (3D-CRT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 3D-conformal-radiation therapy (3D-CRT) with escalated dose (+10 or 15%)
Number of subjects: 0
Study: 8690970

Group type: EXPERIMENTAL
Intervention: THELEP‐recommended regimen (600 mg rifampin, 600 mg clofazimine supervised on two consecutive days monthly, 225 mg diacetyl diaminodiphenylsulfone bimonthly, 100 mg dapsone daily unsupervised)
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Conventional MDT (600 mg rifampin, 300 mg clofazimine supervised once a month, 100 mg dapsone daily unsupervised, 50 mg clofazimine daily unsupervised)
Number of subjects: 1067
Study: 1599110

Group type: EXPERIMENTAL
Intervention: Clonidine (3.5 micrograms.kg-1 orally)
Number of subjects: 5
Study: 6202851

Group type: EXPERIMENTAL
Intervention: Cisplatin (CPL)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Bleomycin, cyclophosphamide, and dactinomycin (BCD)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Fibroblast interferon
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX)
Number of subjects: 158
Study: 29602994

Group type: EXPERIMENTAL
Intervention: Surgical coaching (N=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (N=12)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Surgical coaching
Number of subjects: 24
Study: 27075273

Group type: EXPERIMENTAL
Intervention: Inter-professional education (IPE) course
Number of subjects: 0
Study: 26289764

Group type: EXPERIMENTAL
Intervention: Warm-up procedure (Group 1 - first case of the day)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Post-warm-up procedure (Group 2 - second case of the day)
Number of subjects: 82
Study: 24380385

Group type: EXPERIMENTAL
Intervention: Traditional dietary modifications
Number of subjects: 33

Group type: COMPARATOR
Intervention: Weight reduction advice in the form of an Energy Prescription (EP)
Number of subjects: 33
Study: 20666814

Group type: EXPERIMENTAL
Intervention: Two presurgical skin pretreatment methods (details not specified)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Interoperative irrigation with sterile saline solution
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Phenol application after nail removal
Number of subjects: 48
Study: 18239197

Group type: EXPERIMENTAL
Intervention: 2.0 mg trihexyphenidyl
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 16603147

Group type: EXPERIMENTAL
Intervention: 50 mg Fe daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: 50 mg Fe twice weekly
Number of subjects: 24
Study: 12453547

Group type: EXPERIMENTAL
Intervention: Nebivolol (2.5 and 5 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10511352

Group type: EXPERIMENTAL
Intervention: Endometrial vaporization
Number of subjects: 91

Group type: COMPARATOR
Intervention: Resection using standard cutting loop
Number of subjects: 91
Study: 7717236

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg 20-30 min before cystourethrography
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no midazolam)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.6 mg/kg
Number of subjects: 98
Study: 2038109

Group type: EXPERIMENTAL
Intervention: ibuprofen 800 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 7224205

Group type: EXPERIMENTAL
Intervention: Sterile anesthesia breathing circuits with bacterial filters
Number of subjects: 293

Group type: COMPARATOR
Intervention: Reusable circuit that had been washed and dried after previous use (Control)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 293
Study: 31945548

Group type: EXPERIMENTAL
Intervention: aPDT as an adjunct to ultrasonic scaling (US)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PBM as an adjunct to ultrasonic scaling (US)
Number of subjects: 45

Group type: COMPARATOR
Intervention: US alone
Number of subjects: 45
Study: 31567872

Group type: EXPERIMENTAL
Intervention: Central European diet (CED)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MED)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Central European diet (CED) with minor allele of FADS genes
Number of subjects: 100
Study: 27839807

Group type: EXPERIMENTAL
Intervention: Delayed remote ischemic preconditioning (RIPC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 160
Study: 25499915

Group type: EXPERIMENTAL
Intervention: Physical activity (n=24)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No physical activity (n=10)
Number of subjects: 34
Study: 23802640

Group type: EXPERIMENTAL
Intervention: Ascorbic acid, 500 mg every eight hours, administered three times per day for 48 hours prior to bleaching sessions.
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo, administered three times per day for 48 hours prior to bleaching sessions.
Number of subjects: 39
Study: 21416238

Group type: EXPERIMENTAL
Intervention: Scaling and root planning (SRP)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SRP + subgingival minocycline administration
Number of subjects: 28
Study: 19258143

Group type: EXPERIMENTAL
Intervention: 2 mL of 1% lidocaine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3 mL of 1% lidocaine
Number of subjects: 45

Group type: COMPARATOR
Intervention: 1 mL of 1% lidocaine
Number of subjects: 45
Study: 17445928

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) - 50 Gy/25 fx/5 weeks followed by 12 Gy/2 fx of high-dose-rate intra-lumenal brachytherapy (initially), later modified to 66 Gy/33 fx/6.5 weeks.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cisplatin chemo-radiotherapy (CRT) - identical radiotherapy with concurrent weekly cisplatin at 35 mg/m2 for 6-7 cycles.
Number of subjects: 125

Group type: COMPARATOR
Intervention: Cisplatin (part of CRT)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Late morbidity (ulcers)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Late morbidity (strictures)
Number of subjects: 125
Study: 15028129

Group type: EXPERIMENTAL
Intervention: Tirilazad
Number of subjects: 3567

Group type: COMPARATOR
Intervention: WFNS grading scale
Number of subjects: 3567
Study: 12602080

Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D3
Number of subjects: 1080
Study: 10440800

Group type: EXPERIMENTAL
Intervention: Combined hepatitis A and B vaccine (two-dose schedule)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Monovalent vaccines (two-dose schedule)
Number of subjects: 100
Study: 7761801

Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with narrow-band noise at 80 signs/min
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with narrow-band noise at 150 signs/min
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with broad-band noise at 80 signs/min
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Electronic Morse decoders with broad-band noise at 150 signs/min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Human recognition of Morse signs
Number of subjects: 5
Study: 2117799

Group type: EXPERIMENTAL
Intervention: OKT3 as a prophylactic agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OKT3 in patients with ATN
Number of subjects: 0
Study: 371743

Group type: EXPERIMENTAL
Intervention: Clindamycin (600 mg i.m.)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Cefazolin (1.1 g i.m.)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 238
Study: 30778649

Group type: EXPERIMENTAL
Intervention: Betrixaban for 35-42 days
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Betrixaban (full-dose stratum)
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Betrixaban (overall population)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Enoxaparin for 10±4 days
Number of subjects: 703

Group type: COMPARATOR
Intervention: Enoxaparin (full-dose stratum)
Number of subjects: 703
Study: 28325823

Group type: EXPERIMENTAL
Intervention: Video consultations as add-on to clinic-based care
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard care (clinic-based care)
Number of subjects: 165
Study: 26200171

Group type: EXPERIMENTAL
Intervention: 1.5 litres water per day + stress control and sleep hygiene
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stress control and sleep hygiene
Number of subjects: 102
Study: 23720136

Group type: COMPARATOR
Intervention: Normal-fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting conditions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-fat breakfast
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Protein-rich nutritional drink
Number of subjects: 0
Study: 21999972

Group type: EXPERIMENTAL
Intervention: Group-format behavioral self-management intervention for pain and insomnia
Number of subjects: 367
Study: 20066887

Group type: EXPERIMENTAL
Intervention: Assistive technology and home modification intervention
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard community-available health care (Control)
Number of subjects: 91
Study: 17910330

Group type: EXPERIMENTAL
Intervention: Levocetirizine, 0.125 mg/kg, twice daily for 18 months
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study: 14566153

Group type: EXPERIMENTAL
Intervention: EMG biofeedback
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo EMG biofeedback
Number of subjects: 27
Study: 10971099

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 0
Study: 8877910

Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (13C-UBT) with 38 mg 13C-urea
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: 13C-urea breath test (13C-UBT)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Histology and rapid urease test (CLOtest)
Number of subjects: 114
Study: 1737596

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 25

Group type: COMPARATOR
Intervention: CT
Number of subjects: 25
Study: 6378450

Group type: EXPERIMENTAL
Intervention: Thymic humoral factor (THF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 3741533

Group type: EXPERIMENTAL
Intervention: Intravenous theophylline (0.48 g of theophylline-ethylenediamine, TE)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Retention enema (400 mg theophylline, 600 mg diprophylline, 600 mg proxyphylline, TDP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both TE and TDP
Number of subjects: 16